PDF(Pubmed)
Abstract：
Recent evidence suggests that cyclin-dependent kinase 4/6 (CDK4/6) inhibitors significantly improve progression-free survival and overall survival among metastatic breast cancer patients. However, given the effects on cell cycle arrest, there is potential for CDK4/6 inhibitors and radiotherapy (RT) to work synergistically, enhancing the effect and toxicities of RT. A comprehensive review of the literature on the combination of RT and CDK4/6 inhibitors was performed with 19 eligible studies included in the final analysis. A total of 373 patients who received radiotherapy combined with CDK4/6 inhibitors were evaluated across 9 retrospective studies, 4 case reports, 3 case series, and 3 letters to the editor. The CDK4/6 inhibitor used, RT target, and RT technique were assessed in terms of toxicities. This literature review demonstrates generally limited toxicities with the combination of CDK4/6 inhibitors and palliative radiotherapy to metastatic breast cancer patients. The current evidence is nonetheless limited, and further results of ongoing prospective clinical trials will help clarify whether these treatments can be safely combined.
摘要：
最近的证据表明，细胞周期蛋白依赖性激酶4/6（CDK4/6）抑制剂显着改善转移性乳腺癌患者的无进展生存期和总生存期。然而,考虑到对细胞周期停滞的影响，CDK4/6抑制剂和放疗（RT）有协同作用的潜力，增强RT的效果和毒性。对RT和CDK4/6抑制剂组合的文献进行了全面回顾，最终分析中包括19项符合条件的研究。共373例接受放疗联合CDK4/6抑制剂的患者进行了9项回顾性研究,4例病例报告,3个案例系列，给编辑写了3封信.使用的CDK4/6抑制剂，RT目标,和RT技术在毒性方面进行评估。这篇文献综述表明，CDK4/6抑制剂和姑息性放疗对转移性乳腺癌患者的毒性通常有限。目前的证据是有限的，正在进行的前瞻性临床试验的进一步结果将有助于阐明这些治疗是否可以安全地联合使用.
